Tscan Therapeutics Inc
NASDAQ:TCRX 4:00:00 PM EDT
Market Cap (Intraday) | 80.37M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $1.52 |
50-Day MA | $1.47 |
200-Day MA | $3.04 |
Tscan Therapeutics Inc Stock, NASDAQ:TCRX
830 Winter Street, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.399.9500
Number of Employees: 194
Description
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.